Literature DB >> 25606573

Neuroendocrine differentiation of prostate cancer: a review.

Vamsi Parimi1, Rajen Goyal2, Kate Poropatich2, Ximing J Yang3.   

Abstract

Neuroendocrine cells are one of the epithelial populations in the prostate. Neuroendocrine differentiation (NED) has been observed in prostate cancer. In addition to small cell neuroendocrine carcinomas and carcinoid tumors of the prostate, prostatic adenocarcinomas may have NED. The incidence and clinical relevance of NED in prostatic adenocarcinoma is not clearly understood because of conflicting results in the reported studies, and evaluation of NED is not routinely performed in clinical practice. This review is an overall synthesis with an aim to develop a more comprehensive understanding and practical approach towards the current knowledge of neuroendocrine differentiation. In this review we are stratifying these lesions into separate subtypes based on histologic parameters such as tumor morphology, neuroendocrine cell density and distribution and clinical parameters. We also want to identify current controversies and confusing issues not totally resolved in this topic for further investigations. Eventually a clearer understanding of this phenomenon and appropriate handling NED in prostate cancer will benefit clinical practice.

Entities:  

Keywords:  Neuroendocrine differentiation; prostate

Year:  2014        PMID: 25606573      PMCID: PMC4297323     

Source DB:  PubMed          Journal:  Am J Clin Exp Urol        ISSN: 2330-1910


  82 in total

1.  Synaptic vesicle protein 2, A new neuroendocrine cell marker.

Authors:  G M Portela-Gomes; A Lukinius; L Grimelius
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy.

Authors:  M H Weinstein; A W Partin; R W Veltri; J I Epstein
Journal:  Hum Pathol       Date:  1996-07       Impact factor: 3.466

3.  Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment.

Authors:  T Jiborn; A Bjartell; P A Abrahamsson
Journal:  Urology       Date:  1998-04       Impact factor: 2.649

4.  Treatment outcomes of small cell carcinoma of the prostate: a single-center study.

Authors:  Philippe E Spiess; Curtis A Pettaway; Funda Vakar-Lopez; Wassim Kassouf; Xuemei Wang; Joseph E Busby; Kim-Anh Do; Rajayogesh Davuluri; Nizar M Tannir
Journal:  Cancer       Date:  2007-10-15       Impact factor: 6.860

5.  Anti-lymphocyte antibody Leu-7 (HNK-1) recognizes a constituent of neuroendocrine granule matrix.

Authors:  A S Tischler; H Mobtaker; K Mann; G Nunnemacher; W J Jason; Y Dayal; R A Delellis; L Adelman; H J Wolfe
Journal:  J Histochem Cytochem       Date:  1986-09       Impact factor: 2.479

Review 6.  A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008.

Authors:  D M Marcus; M Goodman; A B Jani; A O Osunkoya; P J Rossi
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-02-21       Impact factor: 5.554

7.  Immunohistochemical analysis of the proliferative activity of neuroendocrine tumors from various organs. Are there indications for a neuroendocrine tumor-carcinoma sequence?

Authors:  B Helpap; J Köllermann
Journal:  Virchows Arch       Date:  2001-01       Impact factor: 4.064

Review 8.  Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status.

Authors:  H Bonkhoff
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

9.  Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients.

Authors:  Marko Tarle; M Zaky Ahel; Ksenija Kovacić
Journal:  Anticancer Res       Date:  2002 Jul-Aug       Impact factor: 2.480

10.  A useful treatment for patients with advanced mixed-type small cell neuroendocrine carcinoma of the prostate: A case report.

Authors:  Kei-Ichiro Uemura; Go Nakagawa; Katsuaki Chikui; Fukuko Moriya; Makoto Nakiri; Tokumasa Hayashi; Shigetaka Suekane; Kei Matsuoka
Journal:  Oncol Lett       Date:  2013-01-15       Impact factor: 2.967

View more
  85 in total

1.  Anti-Hu-Mediated Paraneoplastic Chronic Intestinal Pseudo-Obstruction Arising From Small Cell Prostate Cancer.

Authors:  Javier A Cerra-Franco; Carlos Fernandez-Cruz; Rodolfo Estremera-Marcial; Hendrick Pagan-Torres; Jaime Martinez-Souss; Doris H Toro
Journal:  ACG Case Rep J       Date:  2019-07-03

2.  68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

Authors:  Wolfgang P Fendler; Matthias Eiber; Mohsen Beheshti; Jamshed Bomanji; Francesco Ceci; Steven Cho; Frederik Giesel; Uwe Haberkorn; Thomas A Hope; Klaus Kopka; Bernd J Krause; Felix M Mottaghy; Heiko Schöder; John Sunderland; Simon Wan; Hans-Jürgen Wester; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06       Impact factor: 9.236

Review 3.  Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.

Authors:  Emma E van der Toom; Haley D Axelrod; Jean J de la Rosette; Theo M de Reijke; Kenneth J Pienta; Kenneth C Valkenburg
Journal:  Nat Rev Urol       Date:  2019-01       Impact factor: 14.432

Review 4.  Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.

Authors:  Loredana Puca; Panagiotis J Vlachostergios; Himisha Beltran
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

5.  [Neuroendocrine prostate cancer].

Authors:  S Tritschler; R Erdelkamp; C Stief; M Hentrich
Journal:  Pathologe       Date:  2018-07       Impact factor: 1.011

6.  Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer.

Authors:  Rahul Aggarwal; Gustavo Rubio Romero; Verena Friedl; Alana Weinstein; Adam Foye; Jiaoti Huang; Felix Feng; Joshua M Stuart; Eric J Small
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-04-14       Impact factor: 5.554

7.  [Metastatic castration-resistant prostate cancer].

Authors:  Vanessa Henriques; Mike Wenzel; Melanie-Christin Demes; Jens Köllermann
Journal:  Pathologe       Date:  2021-06-25       Impact factor: 1.011

8.  Obstructive Jaundice: An Unusual Presentation of Neuroendocrine Differentiation in Prostatic Adenocarcinoma.

Authors:  Sampath Santhosh; Godwin Jeeva; Ranjan Kumar Mohapatra
Journal:  Indian J Nucl Med       Date:  2021-03-04

9.  Incidental finding of a small cell neuroendocrine carcinoma of the ureter.

Authors:  Obinna Obi-Njoku; Chris Bell; Prashant Ravindran Menon; Iqbal Shergill
Journal:  BMJ Case Rep       Date:  2019-08-01

10.  Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage.

Authors:  Jung Wook Park; John K Lee; Katherine M Sheu; Liang Wang; Nikolas G Balanis; Kim Nguyen; Bryan A Smith; Chen Cheng; Brandon L Tsai; Donghui Cheng; Jiaoti Huang; Siavash K Kurdistani; Thomas G Graeber; Owen N Witte
Journal:  Science       Date:  2018-10-05       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.